biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal
6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 79
- Drugs
- 28
- Patents
- 111
NBI-921352
Phase 2 · small molecule · SCN8A Developmental and Epileptic Encephalopathy Syndrome
NBI-921352 for SCN8A Developmental and Epileptic Encephalopathy Syndrome is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 2 ClinicalTrials.gov record(s).
Internal code NBI-921352-DEE2013
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NEUROCRINE BIOSCIENCES INC
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Status
- active
- Trials
- 2